Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free NFX Stock Alerts

Nuformix (NFX) Competitors

Nuformix logo
GBX 0.16 +0.00 (+0.63%)
As of 11:25 AM Eastern
Compare

NFX vs. CLBX, FAB, NSCI, APTA, and GENF

Should you buy Nuformix stock or one of its competitors? Nuformix's main competitors and comparable companies include Cellbxhealth (CLBX), Fusion Antibodies (FAB), NetScientific (NSCI), Aptamer Group (APTA), and Genflow Biosciences (GENF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuformix compare to Cellbxhealth?

Cellbxhealth (LON:CLBX) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Cellbxhealth has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M11.84N/A-£3.49N/A
NuformixN/AN/A-£383.40K-£0.03N/A

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cellbxhealth's return on equity of 0.00% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Nuformix N/A -83.53%-17.20%

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Nuformix Neutral

Summary

Cellbxhealth beats Nuformix on 5 of the 7 factors compared between the two stocks.

How does Nuformix compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nuformix has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.57-£4.10M-£1.50N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Fusion Antibodies has a beta of 1.224, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.519, indicating that its stock price is 52% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Nuformix N/A -83.53%-17.20%

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Nuformix Neutral

Summary

Nuformix beats Fusion Antibodies on 8 of the 10 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

NetScientific (LON:NSCI) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

NetScientific has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.519, indicating that its stock price is 52% more volatile than the broader market.

Nuformix has lower revenue, but higher earnings than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
NuformixN/AN/A-£383.40K-£0.03N/A

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Nuformix Neutral

14.7% of NetScientific shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 42.4% of NetScientific shares are owned by company insiders. Comparatively, 7.5% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Nuformix N/A -83.53%-17.20%

Summary

NetScientific beats Nuformix on 6 of the 10 factors compared between the two stocks.

How does Nuformix compare to Aptamer Group?

Nuformix (LON:NFX) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Nuformix has a beta of 1.519, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, indicating that its stock price is 10% less volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Nuformix's return on equity of -83.53% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Aptamer Group -178.52%-135.35%-44.96%

Nuformix has higher earnings, but lower revenue than Aptamer Group. Nuformix is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
Aptamer Group£1.38M9.48-£14.17M-£0.11N/A

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 3.3% of Aptamer Group shares are owned by institutional investors. 7.5% of Nuformix shares are owned by company insiders. Comparatively, 7.3% of Aptamer Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Aptamer Group Neutral

Summary

Nuformix beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

How does Nuformix compare to Genflow Biosciences?

Nuformix (LON:NFX) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Nuformix has a beta of 1.519, meaning that its share price is 52% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.268, meaning that its share price is 127% more volatile than the broader market.

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 7.5% of Nuformix shares are owned by insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nuformix has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Genflow Biosciences -170.64%332.06%-58.66%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Genflow Biosciences Neutral

Summary

Nuformix beats Genflow Biosciences on 6 of the 9 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

Export
MetricNuformixBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£4.18M£4.02B£7.21B£2.89B
Dividend YieldN/A3.61%2.54%6.17%
P/E Ratio-5.4612.31273.21364.82
Price / SalesN/A1,403.34639.2683,676.90
Price / Cash3.55106.6377.2027.89
Price / Book0.3016.2112.866.75
Net Income-£383.40K-£22.72M£3.47B£5.89B
7 Day Performance-1.84%-1.18%-0.22%-0.78%
1 Month Performance14.29%12.75%8.04%2.38%
1 Year Performance52.38%53.86%25.08%22.66%

Nuformix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
N/AGBX 0.16
+0.6%		N/A+71.0%£4.18MN/AN/A3
CLBX
Cellbxhealth
N/AGBX 1.27
+1.2%		N/AN/A£14.38M£1.15MN/AN/A
FAB
Fusion Antibodies
N/AGBX 10.88
+3.6%		N/A-17.2%£13.62M£1.60MN/A48
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
APTA
Aptamer Group
N/AGBX 0.35
-6.4%		N/A-70.1%£12.13M£1.38MN/A37

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
What the Mainstream Media Gets Wrong About IPO Investing
Jason Bodner spent nearly two decades helping IPOs go to market. Now he says an overlooked group of companies ...
Brownstone Research | Sponsoredtc pixel
This Gold Fund Could Outyield Newmont With Far Less Capital
Put $24,000 into Newmont and you'd collect about $240 a year - a 1% yield that barely covers groceries. A l...
Investors Alley | Sponsoredtc pixel
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...
Stansberry Research | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel